JP7905369B2 - 腎臓活性融合タンパク質及びそれを使用する治療方法 - Google Patents

腎臓活性融合タンパク質及びそれを使用する治療方法

Info

Publication number
JP7905369B2
JP7905369B2 JP2023572788A JP2023572788A JP7905369B2 JP 7905369 B2 JP7905369 B2 JP 7905369B2 JP 2023572788 A JP2023572788 A JP 2023572788A JP 2023572788 A JP2023572788 A JP 2023572788A JP 7905369 B2 JP7905369 B2 JP 7905369B2
Authority
JP
Japan
Prior art keywords
compound
fusion protein
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023572788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520421A5 (cg-RX-API-DMAC7.html
JP2024520421A (ja
Inventor
キース ブシャール,
ジェフリー ウィリアム ハンター,
ブルース エー. ジュニア アンドリアン,
ソン-クォン キム,
ジュリアン チャンドラー,
Original Assignee
アレクシオン ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ, インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ, インコーポレイテッド
Publication of JP2024520421A publication Critical patent/JP2024520421A/ja
Priority to JP2025086967A priority Critical patent/JP2025116068A/ja
Publication of JP2024520421A5 publication Critical patent/JP2024520421A5/ja
Application granted granted Critical
Publication of JP7905369B2 publication Critical patent/JP7905369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
JP2023572788A 2021-05-25 2022-05-24 腎臓活性融合タンパク質及びそれを使用する治療方法 Active JP7905369B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025086967A JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192835P 2021-05-25 2021-05-25
US63/192,835 2021-05-25
PCT/US2022/030658 WO2022251168A1 (en) 2021-05-25 2022-05-24 Kidney active fusion proteins and methods of treatment using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025086967A Division JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Publications (3)

Publication Number Publication Date
JP2024520421A JP2024520421A (ja) 2024-05-24
JP2024520421A5 JP2024520421A5 (cg-RX-API-DMAC7.html) 2025-06-04
JP7905369B2 true JP7905369B2 (ja) 2026-08-14

Family

ID=84230212

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023572788A Active JP7905369B2 (ja) 2021-05-25 2022-05-24 腎臓活性融合タンパク質及びそれを使用する治療方法
JP2025086967A Pending JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025086967A Pending JP2025116068A (ja) 2021-05-25 2025-05-26 腎臓活性融合タンパク質及びそれを使用する治療方法

Country Status (11)

Country Link
US (1) US20240262877A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347666A4 (cg-RX-API-DMAC7.html)
JP (2) JP7905369B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240013770A (cg-RX-API-DMAC7.html)
CN (1) CN117396519A (cg-RX-API-DMAC7.html)
AU (1) AU2022283254A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024627A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177162A1 (cg-RX-API-DMAC7.html)
IL (1) IL308754A (cg-RX-API-DMAC7.html)
MX (1) MX2023014037A (cg-RX-API-DMAC7.html)
WO (1) WO2022251168A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116472065A (zh) * 2020-10-05 2023-07-21 阿雷克森制药公司 治疗皮肌炎的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527115A (ja) 2000-03-13 2003-09-16 セント ビンセンツ ホスピタル 新規のh因子関連タンパク質5及びその抗体
JP2013520979A (ja) 2010-03-05 2013-06-10 リグショスピタレト 補体活性化のキメラ抑制分子
WO2018075462A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5250548B2 (ja) * 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体h因子の標的化
EP3033093A1 (en) * 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
WO2020041644A1 (en) * 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527115A (ja) 2000-03-13 2003-09-16 セント ビンセンツ ホスピタル 新規のh因子関連タンパク質5及びその抗体
JP2013520979A (ja) 2010-03-05 2013-06-10 リグショスピタレト 補体活性化のキメラ抑制分子
WO2018075462A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GILMORE C. Alyssa et al.,Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains,Kidney International,2020年10月28日,Vol.99,pp.396-404
HELLWAGE Jens et al.,The human complement regulatory factor-H-like protein 1, which represents a truncated form of factor H, displays cell-attachment activity,Biochem. J.,1997年,Vol.326,pp.321-327

Also Published As

Publication number Publication date
MX2023014037A (es) 2024-01-15
EP4347666A1 (en) 2024-04-10
CN117396519A (zh) 2024-01-12
WO2022251168A9 (en) 2023-02-16
CA3177162A1 (en) 2022-11-25
JP2024520421A (ja) 2024-05-24
JP2025116068A (ja) 2025-08-07
KR20240013770A (ko) 2024-01-30
AU2022283254A9 (en) 2023-12-07
AU2022283254A1 (en) 2023-11-30
US20240262877A1 (en) 2024-08-08
WO2022251168A1 (en) 2022-12-01
BR112023024627A2 (pt) 2024-02-20
IL308754A (en) 2024-01-01
EP4347666A4 (en) 2025-07-16

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260803